Something more than estimating renal dosimetry

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 767-768

  Bodei, Lisa ^a   Cremonesi, Marta ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

CANCER THERAPY; DOSIMETRY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; KIDNEY SIZE; LETTER; NEPHROTOXICITY; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOISOTOPE THERAPY; RENAL DOSIMETRY;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KIDNEY; MODELS, BIOLOGICAL; PAMPHLETS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; RADIATION DOSAGE; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, PEPTIDE;

EID: 78651295474     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0885     Document Type: Letter

References (14)

1. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in pep-tide receptor radionuclide therapy. Cancer Biother Radio-pharm 2010;25:581.
2. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry: Ready for biological effective dose? Cancer Biother Radiopharm 2010;25:589.
3. 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847.
4. Wessels BW, Dale RG, Cremonesi M, et al. Renal dosimetry. Cancer Biother Radiopharm 2010;25:597.
5. Lassmann M, Strigari L, Bardiès M. Dosimetry is alive and well. Cancer Biother Radiopharm 2010;25:593.
6. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response\implications for radionuclide therapy. J Nucl Med 2008;49:1884.
7. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treat-ment with radiolabelled somatostatin analogues: A review. Q J Nucl Med Mol Imag 2010;54:37.
8. Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTA-TOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. Nucl Med 2005;46(suppl1):99S.
9. De Jong M, Valkema R, Van Gameren A, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 2004;45:1168.
10. Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imag 2005;32:1136.
11. Konijnenberg M, Melis M, Valkema R, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134.
12. Bouchet LG, Bolch WE, Blanco HP, et al. MIRD Pamphlet No 19: Absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003;44:1113.
13. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53.
14. Bodei L, Ferone D, Grana CM, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 2009;32:360.